Background In myocardial infarction (MI), it is well known that serum creatine kinase (s-CK) increases after onset, but it is unclear whether s-CK elevates before MI onset. The present analysis examined whether elevated s-CK levels predicted first-ever MI or stroke.
Introduction
Creatine kinase is included mainly in skeletal muscle, cardiac muscle and brain, and is involved in energy production. Serum creatine kinase (s-CK) levels in healthy individuals are influenced by age, sex, race, pregnancy, muscle mass and physical activity, and is well known to be elevated following any damage to or disease of the above-mentioned organs. 1 In myocardial infarction (MI), s-CK levels usually increase within 4-8 h after MI onset and return to normal 48-72 h later. 2 It is unclear, however, whether s-CK elevation occurs before MI onset. If s-CK elevates before MI onset, s-CK elevation might predict MI incidence, and three possible hypotheses for background mechanism can be considered. First, small amounts of intramyocardial proteins such as creatine kinase might leak into serum by microinfarction or ischaemia in myocardium. 3, 4 Secondly, s-CK might be a surrogate marker of hypothyroidism, as recent meta-analyses reported the relationship between hypothyroidism and a modest increased risk for coronary heart diseases. 5, 6 Thirdly, medication for hyperlipidaemia that can occasionally cause rhabdomyolysis with s-CK elevation might be involved. 7, 8 To our knowledge, there has been no previous cohort study that elucidated the association between s-CK levels at baseline and a risk of cardiovascular diseases (CVDs). Therefore, as a first step of testing the above-stated hypotheses, the present analysis examined whether elevated s-CK levels predicted first-ever MIs or strokes in a 12-year populationbased cohort study of a Japanese urban area.
Methods

Study design and samples
The Suita study is a population-based cohort study in an urban area located in the mid-west part of Japan. [9] [10] [11] In 1989, the Suita study randomly sampled 12 200 Japanese men and women, aged 30-79 years, from the Suita city residents by sex and age class (10-year increments). From this sample, 6406 men and women participated in a baseline survey (participation rate: 52.5%) at the National Cardiovascular Center from September 1989 to March 1994, and were enrolled as study subjects. They have been examined every 2 years and followed-up to December 2005.
A total of 1380 subjects were excluded from this analysis for the following reasons: past or present history of MI or stroke at baseline (n ¼ 208); abnormal Q wave on standard 12-lead electrocardiogram (ECG) (n ¼ 3, corresponding to 1-1 in Minnesota code); missing data for s-CK or any other explanatory variables at baseline (n ¼ 330); ST depression on baseline electrocardiogram (corresponding to 4-1 in Minnesota code) or angina on treatment (n ¼ 139); and lost to follow-up (n ¼ 700). Consequently, 5026 initially healthy subjects (2370 men and 2656 women, mean age: 54.5 years) were included in this analysis. Informed consent was obtained from all subjects. This study was approved by the institutional review board at the National Cardiovascular Center.
Baseline data collection A baseline survey included questionnaires, anthropometric measurements, a standard 12-lead ECG and blood sample testing with overnight fasting (510 h). Height and weight were measured in light clothing, and body mass index was calculated as weight (kilograms) divided by height (square metres). Blood pressure of subjects was measured three times by well-trained physicians in a sitting position after 55 min of rest, using a standard mercury sphygmomanometer. Blood sample tests included serum total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, creatinine, creatine kinase and fasting plasma glucose (FPG), and all samples were immediately centrifuged after blood sampling and analysed by an automatic analyser at the laboratory of the National Cardiovascular Center. Creatine kinase was measured in serum with the Japan Society of Clinical Chemistry (JSCC) method.
The standard 12-lead ECGs were double-checked and coded with Minnesota code by well-trained physicians. 12, 13 Physicians or nurses administrated questionnaires for life styles and past medical history. Current cigarette use was defined as smoking at least one cigarette a day. Current alcohol consumption was defined as drinking alcohol at least once a week.
Ascertainment of MI or stroke events
Details for the ascertainment of MI or stroke events were previously described elsewhere. [9] [10] [11] To detect MI or stroke events, each subject's health status was checked by physicians or nurses at clinical visits to the National Cardiovascular Center every 2 years. In addition, yearly questionnaires by mail or telephone were also completed for all participants. Those who reported to have developed MI or stroke were confirmed by a review of medical records after informed consent was obtained from each individual. Medical record review was performed by physicians at either the registered hospitals or the administration office of this cohort study. The percentage of informed consents obtained for medical record review was 86.2%.
With regard to MI, definite and probable MI was defined according to the criteria set out by the MONICA project, which requires evidence from ECGs, cardiac enzymes and/or autopsy.
14 Strokes were defined according to the National Survey of Stroke criteria, which require the rapid onset of a series of neurological deficits lasting 524 h or until death. For each stroke subtype [i.e. cerebral infarction (thrombotic or embolic infarction), intracerebral haemorrhage and subarachnoid haemorrhage], a definite diagnosis was established, based on examination of computed tomographic scans, magnetic resonance images or autopsies. 15 In order to complete the surveillance for fatal stroke and MI, we also conducted a systematic search of death certificates (all death certificates in Japan are forwarded to the Ministry of Health, Welfare and Labour and coded for National Vital Statistics) for the following subjects: (i) those without informed consent for medical records survey to confirm MI or stroke events that were detected at regular visits to the National Cardiovascular Center or by annual questionnaires; and (ii) those with death certificates who had not been in our register of MI or stroke events. These subjects were defined as probable stroke or MI.
Statistical analysis s-CK levels were divided into four categories with 100 IU/l increments (i.e. 499, 100-199, 200-299, 5300) to compare baseline characteristics and calculate overall and sex-specific crude incidence rates (per 1000 person-years) by the following subtypes of CVD: all MI (including probable and definite MI), definite MI, all strokes, cerebral infarction and haemorrhagic or unclassified strokes. Hypertension was defined as systolic blood pressure 5140 mmHg, diastolic blood pressure 590 mmHg or use of anti-hypertensive medication. Impaired fasting glucose or diabetes was defined as FPG 56.1 mmol/l (110 mg/dl) or use of anti-diabetic medication. Hypercholesterolaemia was defined as total cholesterol 55.7 mmol/l (220 mg/dl) or use of anti-hypercholesterolemic medication. Hypertriglyceridaemia was defined as triglycerides 51.7 mmol/l (150 mg/dl) or use of antihypertriglyceridemic medication. Low HDL-cholesterolaemia was defined as HDL cholesterol 41.0 mmol/l (39 mg/dl).
s-CK levels of 5200 IU/l were unified into one category (i.e. creating three categories with 100 IU/l increments: 499, 100-199 and 5200) to estimate age-and multiple-adjusted hazard ratios (HRs), using a Cox regression model with a reference category of s-CK of 499 IU/l. This is because the number of subjects and events in s-CK levels of 5300 IU/l was substantially smaller than other categories and because crude incidence rates of s-CK levels of 5300 IU/l were also similar with those of s-CK of 200-299 IU/l. Categories of s-CK levels were entered into models as dummy variables. Men and women were combined in estimating HRs with 95% confidence interval (95% CI) because there was no interaction between sex and s-CK levels. Each model adjusted for the following confounding factors: Model 1 adjusted for age; Model 2 adjusted for age, sex, body mass index, hypertension, impaired fasting glucose or diabetes, hypercholesterolaemia, hypertriglyceridaemia, low HDL-cholesterolaemia, creatinine, current cigarette use and current alcohol consumption. Three additional analyses were conducted in Model 2 for definite MI: one excluded 111 further subjects with 4-2, 4-3 in Minnesota code (n ¼ 4915, number of MI events ¼ 45), another further adjusted for regular physical activity habits (yes or no; 224 subjects were excluded because of missing data, n ¼ 4802, number of MI events ¼ 45) and the other excluded 51 subjects in the 99th percentile or higher of s-CK (n ¼ 4975, number of MI events ¼ 44).
The follow-up period of each participant was divided into four categories (0.20-3.30 years, 3.31-4.99 years, 5.00-8.40 years and 8.41-13.89 years), each of which included an equal number of subjects with definite MI. In each category, the median baseline s-CK levels were compared between subjects with and without definite MI in order to examine whether a specific period of follow-up was involved in the present results.
With regard to definite MI, interactions between s-CK levels and each of several confounding factors (i.e. hypercholesterolaemia, hypertriglyceridaemia, low HDL-cholesterolaemia, hypertension, impaired glucose tolerance or diabetes, current cigarette use and current alcohol consumption) were tested by adding the interaction term to Model 2. HRs by s-CK levels and confounding factors were estimated, adjusting for the same factors as Model 2 except for the stratifying factor of each interaction.
The P-value for trend was calculated to test for linearity of HRs. For blood pressure, a third measurement was adopted in all analyses. All P-values were two-tailed.
Results
The overall distribution of baseline s-CK levels (minimum, 25th percentile, median, 75th percentile, maximum) for men was 30, 101, 132, 176 and 3547 IU/l, respectively, and for women it was 25, 87, 110, 141 and 1820 IU/l, respectively. There were 1.0% of men and 0.3% of women with s-CK levels of 5500 IU/l.
Baseline characteristics are shown by s-CK levels in Table 1 . Regardless of sex, body mass index and creatinine tended to increase with elevation in s-CK levels, and the prevalence of current cigarette smoker decreased with elevation in s-CK levels. In women, higher s-CK levels were associated with an increased prevalence of hypertension, hypercholesterolaemia and hypertriglyceridaemia.
Study subjects were followed for 11.8 years on average, and 103 MIs (definite: 45; probable: 58) and 168 strokes (definite: 126; probable: 42) were observed. Strokes were comprised of 27 intracerebral haemorrhages, 106 cerebral infarctions, 20 subarachnoid haemorrhages and 15 unclassified strokes. The follow-up period among those with definite MI was from 0.20 to 13.89 years.
Median baseline s-CK levels were higher among subjects with definite MI than among subjects without definite MI, regardless of the follow-up period (Figure 1 ).
Overall and sex-specific crude incidence rates were presented by s-CK levels and CVD subtype (Table 2) . Overall, incidence rates of MI or stroke were higher in men than in women, and rates of stroke were higher than MI. Overall or sex-specific crude incidence rates of definite MI tended to be higher in subjects with s-CK levels of 5200 IU/l, compared to subjects with levels of 4199 IU/l. Regarding all strokes, this relationship was unclear, although the incidence rate of cerebral infarction in subjects with s-CK levels of 5200 IU/l was slightly higher than in subjects with levels of 4199 IU/l. Age-and multiple-adjusted HRs are shown in Table 3 . Compared with the reference group (499 IU/l), the adjusted HRs for definite and all MI in subjects with s-CK levels of 5200 IU/l were 4.18 (95% CI 1.66-10.53) and 2.06 (95% CI 1.15-3.70), respectively, in Model 2, and were also linearly elevated with increased s-CK levels, regardless of the model.
In Model 2 for definite MI, excluding further subjects with ST depression on the standard 12-lead ECG, corresponding to 4-2, 4-3 and 4-1 in Minnesota code, or adjusting regular physical activity habits had little effect on the results. In addition, excluding 51 subjects in the 99th percentile or higher of s-CK from the analysis also hardly altered the results. No relationships were observed between s-CK levels and risk for all strokes or cerebral infarction.
For definite MI, interactions between lipid status (hypercholesterolaemia, hypertriglyceridaemia, low HDL-cholesterolaemia) and s-CK levels were shown in Table 4 . Interactions in hypercholesterolaemia were observed (P for interaction ¼ 0.011). Among those subjects with hypercholesterolaemia, HRs were linearly elevated, and the HR in s-CK levels of 5200 IU/l was 10.05 (95% CI 2.74-36.81). Similar interaction and linear elevations of HRs were observed among subjects with hypertriglyceridaemia (P for interaction ¼ 0.033) or low-HDL cholesterolaemia (P for interaction ¼ 0.036). Interactions between other confounding factors (hypertension, impaired glucose tolerance or diabetes, current cigarette use and current alcohol consumption) and s-CK levels were not observed: P for interaction in hypertension, 0.94; for impaired glucose tolerance or diabetes, 0.85; for current cigarette smoking, 0.87; and for current alcohol drinking, 0.96 (data not shown).
There were 45 subjects with definite MI during follow-up: 31 subjects with s-CK of 4199 IU/l, and 14 subjects with s-CK of 5200 IU/l (maximum s-CK was 421 IU/l). Among these 45 definite MI subjects, there was one subject with medication for hypercholesterolaemia and s-CK of 4199 IU/l, one with medication for hypertriglyceridaemia and s-CK of 5200 IU/l, nine with medication for hypertension (seven with s-CK of 4199 IU/l, two with s-CK of 5200 IU/l), and four with medication for diabetes and s-CK of 4199 IU/l (data not shown).
Baseline s-CK distribution or other CVD risk factor profiles did not differ so much between 700 individuals (360 men and 340 women) excluded for loss to followup and 5026 study subjects as follows, respectively; s-CK distribution (IU/l) (25th percentile, median, 
Discussion
This is the first report of a prospective cohort study in which elevated s-CK levels at baseline predicted firstever MI. Elevated s-CK levels were associated with a moderately increased risk for MI. On the other hand, there was no association observed between s-CK and a risk for stroke. Therefore, elevated s-CK was a specific predictor for MI in the present analysis. In addition, an interaction between s-CK levels and dyslipidaemia (hypercholesterolaemia, hypertriglyceridaemia, low-HDL cholesterolaemia) was observed. S-CK elevation might be a stronger predictor for MI among subjects with dyslipidaemia.
On the basis of present results, following three possible hypotheses could be considered. One hypothesis is the involvement of hypothyroidism that often accompanies both s-CK elevation and dyslipidaemia including hypercholesterolaemia. 16 On the basis of this hypothesis, s-CK elevation is supposed to be a surrogate marker of hypothyroidism. Although the association between hypothyroidism and coronary heart disease is still controversial, 17-20 recent metaanalyses suggested an association between hypothyroidism and a modest increased risk for coronary heart disease. 5, 6 On the other hand, there were few studies demonstrating causal relationship between hypothyroidism and stroke. 19, 21, 22 Present results also demonstrated no relationship between stroke and s-CK elevation, and were consistent with that. Influence of hypothyroidism on stroke might not be as strong as coronary heart disease. It might be partly A second possible hypothesis is that very small infarction or vulnerability of myocardium might precede clinical MI onset. 3, 4 That is, a small amount of intramyocardial protein leakage might occur after micro-MI, or it may follow reversible disturbance of myocardium because permeability of the myocardial cell membrane is metabolically controlled. s-CK elevation might be an indicator that can detect micro-MI or vulnerability before any symptoms or ECG change appears. In this hypothesis, it might be reasonable that s-CK elevation does not predict stroke because s-CK elevation is due to leakage from myocardium.
A third hypothesis is that medication for hyperlipidaemia can occasionally cause rhabdomyolysis of various degrees with s-CK elevation, 7, 8 and is prescribed to individuals with hyperlipidaemia who are possibly at high risk for MI. Therefore, it could become a confounder for an association between s-CK and MI. However, we thought that this hypothesis had little influence on the present results because there was just one subject medicated for hyperlipidaemia at baseline among those with both definite MI and s-CK of 5200 IU/l. We have no information for creatine kinase isozyme that is important to elucidate the background mechanism. Since s-CK in the present study was just one of screening measurements for CVD in the health check-up to healthy individuals that was conducted almost 20 years before, we did not measure creatine kinase isozyme at baseline. Therefore, we can neither infer a further mechanism nor positively support any of above-mentioned hypotheses.
A cross-sectional study demonstrated a positive association between s-CK and blood pressure, and hypothesized that elevated s-CK levels reflected high tissue creatine kinase activity, which might cause higher blood pressure levels. 24 The present analysis of baseline characteristics also demonstrated the possibility of a positive association between hypertension and s-CK levels in women. If this hypothesis is correct, s-CK levels might also be considered a risk factor for stroke. However, results from the present study were not consistent with this hypothesis.
To assure validity of our analysis, it was very important to exclude MI with a past or present history of MI. First, this analysis excluded the subjects with a medical history of MI, abnormal Q-wave or ST depression on ECG at the baseline survey. Additionally, no subject who had developed MI just at baseline was included (the follow-up period among those with definite MI was, at earliest, 0.20 years). Secondly, regardless of the follow-up period duration, median baseline s-CK levels among subjects with definite MI were higher than among those without ELEVATED s-CK PREDICTS FIRST-EVER MI definite MI. As seen in Figure 1 , even with a followup period of 58.41 years, median s-CK level among subjects with definite MI was higher than among those without definite MI. This suggested that an association between s-CK levels and MI in a specific period did not influence the present results. Therefore, the possibility that any obviously biased data collection for MI events affected the present results seemed to be low. The present study had several limitations except for the above-mentioned creatine kinase isozyme. First, since we did not measure thyroid function including thyroid-stimulating hormone at baseline, we could not estimate the involvement of hypothyroidism with the present results. Secondly, we did not collect medical history, such as muscle diseases, thyroid diseases, medications causing rhabdomyolysis or recent history of severe physical training, all of which might affect s-CK levels. Therefore, we could not completely rule out the existence of unknown confounding factors. Thirdly, the single s-CK measurement at baseline may have underestimated the relationship between s-CK levels and CVD due to regression dilution bias. 25 Fourthly, the participation rate at baseline was not so high, but those of other population-based cohort studies in Japan with baseline clinical laboratory data were similar, [26] [27] [28] [29] except for large cohort studies with baseline survey by questionnaires. 30, 31 Especially in urban areas, the participation rates in cohort studies tend to be lower because the urban residents generally have more opportunities for health check-up than the rural population. 29 That is, the present participation rate was not always low. Moreover, previous reports in the present cohort showed reasonable causal relationship among blood pressure, low-density lipoprotein cholesterol or metabolic syndrome and CVD, [9] [10] [11] which were similar with previous findings from the Japanese cohort studies. 23 This indirectly suggested that the results from the present cohort and analysis were not extremely biased by participation rates or loss to follow-up.
In conclusion, the present study suggested that screening for elevated s-CK levels in initially healthy Japanese subjects was useful to predict first-ever MI in the future, especially in subjects with dyslipidaemia. However, since the present study was conducted in a limited Japanese population with a relatively low MI incidence rate and had several limitations, these findings should be interpreted carefully and examined by further studies in various populations, races and areas. 
